EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression

Tingting Yan, Nana Yan, Yangliu Xia, Vorthon Sawaswong, Xinxin Zhu, Henrique Bregolin Dias, Daisuke Aibara, Shogo Takahashi, Keisuke Hamada, Yoshifumi Saito, Guangming Li, Hui Liu und 9 weitere

Journal of Clinical Investigation · 01.04.2024 · 134 (7)

DOI: 10.1172/jci166731 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.04.2024. Verfasst von Tingting Yan und 20 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: CCAAT-Enhancer-Binding Protein-alpha, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NLM NIH HHS, National Cancer Institute Intramural Research Program, National Institutes of Diabetes and Digestive and Kidney Diseases Intramural Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction–associated steatohepatitis (MASH) — previously described as nonalcoholic steatohepatitis (NASH) — is a major driver of liver fibrosis in humans, while liver fibrosis is a key determinant of all-cause mortality in liver disease independent of MASH occurrence. CCAAT/enhancer binding protein α (CEBPA), as a versatile ligand-independent transcriptional factor, has an important function in myeloid cells, and is under clinical evaluation for cancer therapy. CEBPA is also expressed in hepatocytes and regulates glucolipid homeostasis; however, the role of hepatocyte-specific CEBPA in modulating liver fibrosis progression is largely unknown. Here, hepatic CEBPA expression was found to be decreased during MASH progression both in humans and mice, and hepatic CEBPA mRNA was negatively correlated with MASH fibrosis in the human liver. Cebpa ΔHep mice had markedly enhanced liver fibrosis induced by a high-fat, high-cholesterol, high-fructose diet or carbon tetrachloride. Temporal and spatial hepatocyte-specific CEBPA loss at the progressive stage of MASH in Cebpa ΔHep,ERT2 mice functionally promoted liver fibrosis. Mechanistically, hepatocyte CEBPA directly repressed Spp1 transactivation to reduce the secretion of osteopontin, a fibrogenesis inducer of hepatic stellate cells. Forced hepatocyte-specific CEBPA expression reduced MASH-associated liver fibrosis. These results demonstrate an important role for hepatocyte-specific CEBPA in liver fibrosis progression, and may help guide the therapeutic discoveries targeting hepatocyte CEBPA for the treatment of liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CCAAT-Enhancer-Binding Protein-alphaNon-alcoholic Fatty Liver DiseaseHumansMiceAnimalsHepatocytesLiver CirrhosisLiverDisease Models, Animal

Stichwörter der Autor:innen

FibrosisHepatologyMacrophagesTranscription

Substanzen

CCAAT-Enhancer-Binding Protein-alpha

Autor:innen und Institutionen

  • Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • State Key Laboratory of Natural Medicines, Laboratory of Metabolic Regulation and Drug Target Discovery, China Pharmaceutical University, Nanjing, China.
  • Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, and Beijing Key Laboratory…
  • General Surgery Center and.
  • Department of Pathology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
  • Cancer and Stem Cell Epigenetics, Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute and.

Förderung

  • NLM NIH HHS
  • National Cancer Institute Intramural Research Program
  • National Institutes of Diabetes and Digestive and Kidney Diseases Intramural Research Program
  • National Natural Science Foundation of China
  • Overseas Expertise Introduction Project for Discipline Innovation
  • The Liver and Tissue Cell Distribution System funded by NIH Contract
  • Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka Public Health Promotion Organization Cancer Research Fund and KAKENHI
  • Development and Promotion of Science and Technology Talents Project (DPST), the Royal Thai Government

Zitieren

APA

Yan, T., Yan, N., Xia, Y., Sawaswong, V., Zhu, X., Dias, H. B., Aibara, D., Takahashi, S., Hamada, K., Saito, Y., Li, G., Liu, H., Yan, H., Velenosi, T. J., Krausz, K. W., Huang, J., Kimura, S., Rotman, Y., Qu, A., …, & Gonzalez, F. J. (2024). Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression. Journal of Clinical Investigation, 134(7). https://doi.org/10.1172/jci166731

Vancouver

Yan T, Yan N, Xia Y, Sawaswong V, Zhu X, Dias HB, et al. Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression. Journal of Clinical Investigation. 2024;134(7). doi:10.1172/jci166731

BibTeX
@article{Yan2024,
  author = {Yan, Tingting and Yan, Nana and Xia, Yangliu and Sawaswong, Vorthon and Zhu, Xinxin and Dias, Henrique Bregolin and Aibara, Daisuke and Takahashi, Shogo and Hamada, Keisuke and Saito, Yoshifumi and Li, Guangming and Liu, Hui and Yan, Hualong and Velenosi, Thomas J and Krausz, Kristopher W and Huang, Jing and Kimura, Shioko and Rotman, Yaron and Qu, Aijuan and Hao, Haiping and Gonzalez, Frank J},
  title = {Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {7},
  doi = {10.1172/jci166731}
}
Kostenlos starten →